SB1518, a novel JAK2/FLT3 inhibitor for the treatment of myeloid malignancies

被引：0

作者：

Hart, Stefan ^{[1
]}

Goh, Kee Chuan ^{[1
]}

Novotny-Diermayr, Veronica Veronica ^{[1
]}

Tan, Yong Cheng ^{[1
]}

Madan, Babita ^{[1
]}

Amalini, Chithra ^{[1
]}

Loh, Yung Kiang ^{[1
]}

Ong, Lai Chun ^{[1
]}

Williams, Anthony ^{[1
]}

Lee, Angeline ^{[1
]}

Poulsen, Anders ^{[1
]}

Jayaraman, Ramesh ^{[1
]}

Ethirajulu, Kantharaj ^{[1
]}

Dymock, Brian W. ^{[1
]}

Wood, Jeanette M. ^{[1
]}

机构：

[1] S BIO PTE LTD, Singapore, Singapore

来源：

CANCER RESEARCH | 2011年 / 71卷

关键词：

D O I：

10.1158/1538-7445.AM2011-3570

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3570

引用

页数：1

共 50 条

[1] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
Hart, S.
Goh, K. C.
Novotny-Diermayr, V.
Tan, Y. C.
Madan, B.
Amalini, C.
Ong, L. C.
Kheng, B.
Cheong, A.
Zhou, J.
Chng, W. J.
Wood, J. M.
BLOOD CANCER JOURNAL, 2011, 1 : e44 - e44
[2] Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
S Hart
K C Goh
V Novotny-Diermayr
Y C Tan
B Madan
C Amalini
L C Ong
B Kheng
A Cheong
J Zhou
W J Chng
J M Wood
Blood Cancer Journal, 2011, 1 : e44 - e44
[3] Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis
Verstovsek, Srdan
Deeg, H. Joachim
Odenike, Olatoyosi
Zhu, Joy
Kantarjian, Hagop
Estrov, Zeev
Scott, Bart Lee
Thomas, Deborah A.
BLOOD, 2010, 116 (21) : 1271 - 1271
[4] SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
Hart, S.
Goh, K. C.
Novotny-Diermayr, V.
Hu, C. Y.
Hentze, H.
Tan, Y. C.
Madan, B.
Amalini, C.
Loh, Y. K.
Ong, L. C.
William, A. D.
Lee, A.
Poulsen, A.
Jayaraman, R.
Ong, K. H.
Ethirajulu, K.
Dymock, B. W.
Wood, J. W.
LEUKEMIA, 2011, 25 (11) : 1751 - 1759
[5] SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S Hart
K C Goh
V Novotny-Diermayr
C Y Hu
H Hentze
Y C Tan
B Madan
C Amalini
Y K Loh
L C Ong
A D William
A Lee
A Poulsen
R Jayaraman
K H Ong
K Ethirajulu
B W Dymock
J W Wood
Leukemia, 2011, 25 : 1751 - 1759
[6] CHARACTERIZATION OF THE PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF PACRITINIB (SB1518), A NOVEL ORAL JAK2/FLT3 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS, AML AND LYMPHOMA
Al-Fayoumi, S.
Wang, L.
Dean, J.
Benner, S.
HAEMATOLOGICA, 2013, 98 : 406 - 406
[7] Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma
Lee, Angeline
William, Anthony
Poulsen, Anders
Tan, Evelyn
Nagaraj, Harish
Goh, Kay Lin
Ong, Wai Chung
Goh, Kee Chuan
Pasha, Mohammed Khalid
Jayaraman, Ramesh
Ethirajulu, Kantharaj
Wood, Jeanette M.
Dymock, Brian W.
CANCER RESEARCH, 2011, 71
[8] SB1518: A potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders.
Goh, Kee C.
Ong, Wai C.
Hu, Changyong
Hentze, Harries
Liang, Ai L.
Stunkel, Walter
Tan, Yong C.
Sangthongpitag, Kanda
Goh, Siok K.
Sieh, Shirly
Bonday, Zahid Q.
William, Anthony D.
Lee, Angeline
Llanchard, Stephanie
Liu, Te C.
Sattler, Martin
Griffin, James D.
Dymock, Brian W.
Kantharaj, Ethirajulu
Wood, Jeanette M.
BLOOD, 2007, 110 (11) : 165A - 166A
[9] Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis
Deeg, H. J.
Odenike, O.
Scott, B. L.
Estrov, Z.
Cortes, J. E.
Thomas, D. A.
Zhu, H. J.
Kantarjian, H.
Verstovsek, S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[10] Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia Polycythemia Vera Myelofibrosis
Verstovsek, Srdan
Odenike, Olatoyosi
Scott, Bart
Estrov, Zeev
Cortes, Jorge
Thomas, Deborah A.
Wood, Jeanette
Ethirajulu, Kantharaj
Lowe, Ann
Zhu, Huan J.
Kantarjian, Hagop
Deeg, H. Joachim
BLOOD, 2009, 114 (22) : 1502 - 1502

← 1 2 3 4 5 →